BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 11368889)

  • 1. Combined effects of AT(1) and ET(A) receptor antagonists, candesartan, and A-127722 in DOCA-salt hypertensive rats.
    Pollock DM; Derebail VK; Yamamoto T; Pollock JS
    Gen Pharmacol; 2000 May; 34(5):337-42. PubMed ID: 11368889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ETA receptor blockade attenuates the hypertension but not renal dysfunction in DOCA-salt rats.
    Allcock GH; Venema RC; Pollock DM
    Am J Physiol; 1998 Jul; 275(1):R245-52. PubMed ID: 9688985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic angiotensin blockade with candesartan cilexetil in DOCA/salt hypertensive rats reduces cardiac hypertrophy and coronary resistance without affecting blood pressure.
    Fujita H; Takeda K; Miki S; Morimoto S; Kawa T; Uchida A; Itoh H; Nakata T; Sasaki S; Nakagawa M
    Hypertens Res; 1997 Dec; 20(4):263-7. PubMed ID: 9453261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of chronic treatment with two different ET(A) selective endothelin receptor antagonists on blood pressure and small artery structure of deoxycorticosterone acetate (DOCA)-salt hypertensive rats.
    Li JS; Turgeon A; Schiffrin EL
    Am J Hypertens; 1998 May; 11(5):554-62. PubMed ID: 9633791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system.
    Brown L; Duce B; Miric G; Sernia C
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S143-8. PubMed ID: 9892155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candesartan cilexetil protects against loss of autoregulatory efficiency in angiotensin II-infused rats.
    Inscho EW; Imig JD; Deichmann PC; Cook AK
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S178-83. PubMed ID: 9892160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective antagonism of endothelin ET(A) or ET(B) receptor in renal hemodynamics and function of deoxycorticosterone acetate-salt-induced hypertensive rats.
    Matsumura Y; Taira S; Kitano R; Hashimoto N; Kuro T
    Biol Pharm Bull; 1999 Aug; 22(8):858-62. PubMed ID: 10480326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats.
    Wada T; Kanagawa R; Ishimura Y; Inada Y; Nishikawa K
    J Hypertens; 1995 Jan; 13(1):113-22. PubMed ID: 7759841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats.
    Matsumura Y; Hashimoto N; Taira S; Kuro T; Kitano R; Ohkita M; Opgenorth TJ; Takaoka M
    Hypertension; 1999 Feb; 33(2):759-65. PubMed ID: 10024341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary vascular reactivity is improved by endothelin A receptor blockade in DOCA-salt hypertensive rats.
    Giulumian AD; Pollock DM; Clarke N; Fuchs LC
    Am J Physiol; 1998 Jun; 274(6):R1613-8. PubMed ID: 9608015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats.
    Schiffrin EL; Turgeon A; Deng LY
    Br J Pharmacol; 1997 Jul; 121(5):935-40. PubMed ID: 9222550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin ET(A) receptor antagonism.
    Ammarguellat F; Larouche I; Schiffrin EL
    Circulation; 2001 Jan; 103(2):319-24. PubMed ID: 11208696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of acute AT1 receptor blockade by candesartan on arterial pressure and renal function in rats.
    Cervenka L; Wang CT; Navar LG
    Am J Physiol; 1998 May; 274(5):F940-5. PubMed ID: 9612332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin AT1 receptor antagonism and protection against cardiovascular end-organ damage.
    Nishikawa K
    J Hum Hypertens; 1998 May; 12(5):301-9. PubMed ID: 9655651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment with ibuprofen and the AT1 receptor antagonist candesartan in young spontaneously hypertensive rats.
    Pollock DM; Morsing P
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S116-9. PubMed ID: 9892151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis in aorta of deoxycorticosterone acetate-salt hypertensive rats: effect of endothelin receptor antagonism.
    Sharifi AM; Schiffrin EL
    J Hypertens; 1997 Dec; 15(12 Pt 1):1441-8. PubMed ID: 9431850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
    Fridman K; Andersson OK; Wysocki M; Friberg P; Sunzel M
    Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal responses of the nonclipped kidney of two-kidney/one-clip Goldblatt hypertensive rats to type 1 angiotensin II receptor blockade with candesartan.
    Cervenka L; Navar LG
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S197-201. PubMed ID: 9892163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin-1 expression in blood vessels of DOCA-salt hypertensive rats treated with the combined ETA/ETB endothelin receptor antagonist bosentan.
    Larivière R; Sventek P; Thibault G; Schiffrin EL
    Can J Physiol Pharmacol; 1995 Mar; 73(3):390-8. PubMed ID: 7544236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the ET-1/ETA pathway contributes to erectile dysfunction associated with mineralocorticoid hypertension.
    Carneiro FS; Nunes KP; Giachini FR; Lima VV; Carneiro ZN; Nogueira EF; Leite R; Ergul A; Rainey WE; Clinton Webb R; Tostes RC
    J Sex Med; 2008 Dec; 5(12):2793-807. PubMed ID: 18823320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.